Format

Send to

Choose Destination
J Shoulder Elbow Surg. 2018 May;27(5):777-785. doi: 10.1016/j.jse.2017.11.019. Epub 2018 Jan 11.

Effect of recombinant human growth hormone on rotator cuff healing after arthroscopic repair: preliminary result of a multicenter, prospective, randomized, open-label blinded end point clinical exploratory trial.

Author information

1
Department of Orthopaedic Surgery, Seoul National University College of Medicine, Seoul National University Bundang Hospital, Seongnam, Republic of Korea.
2
Department of Orthopaedic Surgery, Konkuk University School of Medicine, Seoul, Republic of Korea.
3
Department of Orthopaedic Surgery, Konkuk University School of Medicine, Seoul, Republic of Korea. Electronic address: kysoos@catholic.ac.kr.
4
Department of Orthopaedic Surgery, Sungkyunkwan University School of Medicine, Samsung Seoul Hospital, Seoul, Republic of Korea.
5
Department of Radiology, Catholic University College of Medicine, Seoul St. Mary's Hospital, Seoul, Republic of Korea.
6
Department of Radiology, Hallym University College of Medicine, Dongtan Sacred Hospital, Hwaseong, Republic of Korea.
7
Department of Orthopaedic Surgery, Catholic University College of Medicine, Seoul St. Mary's Hospital, Seoul, Republic of Korea.
8
Center for Shoulder, Elbow & Sports Medicine, Neon Orthopaedic Clinic, Seoul, Republic of Korea. Electronic address: drpark@naver.com.

Abstract

BACKGROUND:

This study evaluated the effect of systemic injection of recombinant human growth hormone (rhGH) on outcomes after arthroscopic rotator cuff repair.

METHODS:

This multicenter, prospective, randomized, comparative trial, randomized patients who underwent arthroscopic repair of large-sized rotator cuff tears into 3 groups: rhGH 4 mg group (n = 26), rhGH 8 mg group (n = 24) , and control group (n = 26). Sustained release rhGH was injected subcutaneously once weekly for 3 months postoperatively. The healing failure rate (primary end point), fatty infiltration, and atrophy of the supraspinatus muscle, and functional scores (Constant and American Shoulder and Elbow Surgeons scores) were evaluated at 6 months. Range of motion, pain visual analog scale, and serum insulin-like growth factor-1 level were measured at each follow-up.

RESULTS:

The healing failure rate was similar between groups (rhGH 4 mg group, 30.8%; rhGH 8 mg group, 16.7%; and control group, 34.6%; all P > .05) The proportion of severe fatty infiltration (Goutallier grade ≥3) was 20.8% in the rhGH 8 mg group, 23.1% in the rhGH 4 mg group, and 34.6% in the control group (P > .05). Functional outcomes, range of motion, and pain visual analog scale were similar between groups (all P > .05). The rhGH 8 mg group showed more increased peak insulin-like growth factor-1 level (279.43 ng/mL) than the rhGH 4 mg group ((196.82 ng/mL) and control group (186.31 ng/mL), which was not statistically different (all P > .05). No rhGH injection-related major safety issues occurred.

CONCLUSIONS:

This preliminary study showed no statistically significant improvement in healing or outcomes related to the treatment of rhGH after rotator cuff repair. However, further study with more enrolled patients after resetting the rhGH dose or daily administration protocol would be mandatory.

KEYWORDS:

Recombinant human growth hormone; atrophy; fatty infiltration; healing failure; insulin-like growth factor-1; rotator cuff, healing

PMID:
29337026
DOI:
10.1016/j.jse.2017.11.019
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center